Cargando…
In vitro activity of cysteamine against SARS-CoV-2 variants
Global COVID-19 pandemic is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Continuous emergence of new variants and their rapid spread are jeopardizing vaccine countermeasures to a significant extent. While currently available vaccines are effective at prevent...
Autores principales: | Thoene, Jess, Gavin, Robert F., Towne, Aaron, Wattay, Lauren, Ferrari, Maria Grazia, Navarrete, Jennifer, Pal, Ranajit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444157/ https://www.ncbi.nlm.nih.gov/pubmed/36115282 http://dx.doi.org/10.1016/j.ymgme.2022.08.009 |
Ejemplares similares
-
Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants
por: Alonzi, Tonino, et al.
Publicado: (2022) -
Activity of Cysteamine against the Cystic Fibrosis Pathogen Burkholderia cepacia Complex
por: Fraser-Pitt, Douglas, et al.
Publicado: (2016) -
In vitro release and in vivo growth-promoting effects of coated cysteamine in broilers
por: Liu, Youyou, et al.
Publicado: (2023) -
Cysteamine improves the bactericidal efficacy of intra-canal medicaments against Enterococcus faecalis
por: PANDEY, SANKET HANS, et al.
Publicado: (2018) -
A monoclinic polymorph of cysteamine hydrochloride
por: Ahmad, Saeed, et al.
Publicado: (2009)